POLR1C variants and pathophysiology of hypomyelinating leukodystrophy

Takeaway

  • The broad clinical spectrum of RNA polymerase III-related leukodystrophy (Pol III-RLD) is confirmed by the absence of characteristic findings in the current, novel POLR1C variant-expressing familial group.

Why this matters

  • Pol III-RLD is a rare disorder characterized by CNS hypomyelination and corpus callosal atrophy, with clinical manifestations including cerebellar ataxia, hypodontia and hypogonadism; caused by pathogenic variants in the Pol III subunits POLR3A and POLR3B, and more recently, in POLR1C in patients negative for the previous two.

  • The identification of a novel causative variant for Pol III-RLD is important for enhancing understanding of its pathogenesis, with a view to encourage further research and eventual development of more efficient, targeted treatments to improve patient outcomes.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.